ArticleAntimicrobial agents and chemotherapy2010
Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Comprehensive biological evaluation of infuzide as a potent antimicrobial, alone and in combination with gentamicin, linezolid, and minocycline targeting MDRMicrobiology spectrum · 2025Article
- Article
- Redox Impact on Bacterial Macromolecule: A Promising Avenue for Discovery and Development of Novel Antibacterials.Biomolecules · 2022Review
- Discovery of Quinazoline-2,4(1Molecules (Basel, Switzerland) · 2022Article
- Nigericin is effective against multidrug resistant gram-positive bacteria, persisters, and biofilms.Frontiers in cellular and infection microbiology · 2022Article
- Fluoroquinolone heteroresistance, antimicrobial tolerance, and lethality enhancement.Frontiers in cellular and infection microbiology · 2022Review
- The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis.Molecular biology and evolution · 2020Article
- Post-stress bacterial cell death mediated by reactive oxygen species.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration.Antimicrobial agents and chemotherapy · 2018Article
- Dimethyl Sulfoxide Protects Escherichia coli from Rapid Antimicrobial-Mediated Killing.Antimicrobial agents and chemotherapy · 2016Article
- Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.Antimicrobial agents and chemotherapy · 2015Article
- Lethal synergy involving bicyclomycin: an approach for reviving old antibiotics.The Journal of antimicrobial chemotherapy · 2014Article
- Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.The Journal of biological chemistry · 2014Article
- Superoxide-mediated protection of Escherichia coli from antimicrobials.Antimicrobial agents and chemotherapy · 2013Article
- Induction of mycobacterial resistance to quinolone class antimicrobials.Antimicrobial agents and chemotherapy · 2012Article
- Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.Antimicrobial agents and chemotherapy · 2011Article
- Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality.Antimicrobial agents and chemotherapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
An agar-plate assay was adapted to examine aspects of quinolone structure that restrict the emergence of quinolone-mediated quinolone resistance. When Escherichia coli was applied to agar containing nalidixic acid, the number of quinolone-resistant mutants arising during incubation was decreased by raising the drug concentration and by mutations expected to block the induction of the SOS response (recA, lexA); the mutant number was increased by a mutator mutation (ung). The examination of four related fluoroquinolones then revealed that a C-8 methoxy group and an N-ethyl piperazine substituent at C-7 reduced mutant acquisition more effectively than C-8 H and C-7 C-ethyl piperazine groups. The fluoroquinolone that was most effective at restricting mutant acquisition was the most active when lethal activity was measured on agar plates or in liquid medium (as minimal bactericidal concentration). It also exhibited the lowest ratio of mutant MIC to wild-type MIC when it was tested with a set of isogenic gyrase mutants, and it had a low mutant prevention concentration (MPC) relative to MIC. However, a low MPC was less likely to be important in restricting the induced mutant accumulation because a fluoroquinolone N-ethyl piperazine substituent was more effective than a C-ethyl piperazine substituent at reducing mutant accumulation but was less effective at lowering the MPC. An 8-methoxy-quinazoline-2,4-dione was also effective at restricting the accumulation of resistant mutants on agar. Collectively, these data characterize a simple assay for detection of drug-mediated resistance that is sensitive to the structures of GyrA inhibitors. The assay provides a new method for screening quinolones and quinolone-like molecules that complements MPC-based tests for restricting the emergence of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.